retatrutide clinical trials phase 3 Eli Lilly's triple hormone drug delivers 16.8% weight loss in trial. The next generation of weight loss drugs is already in trials. Lilly's retatrutide delivered nearly 17% weight loss Retatrutide Achieves Up to 30.3%

A thoughtfully formulated multi-strain synbiotic delivering 15 billion CFU across 26 strains paired with diverse organic prebiotics to actually feed them reflects the "quality and diversity over sheer quantity" principle better than a single-strain product boasting 100 billion CFU

2024;134 doi: 10.1172/JCI175634

Here we determined the rate constants for the individual redox reactions between PfGrx, a model glutaredoxin from Plasmodium falciparum , and redox-sensitive green fluorescent protein 2 (roGFP2), a model substrate and versatile tool for intracellular redox measurements

Taste receptors of the gut: emerging roles in health and disease [J]

Human tongue neuroanatomy: Nerve supply and motor endplates

Electroacupuncture restores 5-HT system deficit in chronic mild stress-induced depressed rats